POM: Prescription only medicine
This information is intended for use by health professionals
Prostin E2 Vaginal Gel 1 mg.
Each 3 g gel (2.5 ml) syringe contains 1 mg dinoprostone.
For the full list of excipients, see section 6.1.
Semi-translucent, thixotropic gel.
Oxytocic agent. Prostin E2 Vaginal Gel is indicated for the induction of labour, when there are no foetal or maternal contra-indications.
In primigravida patients with unfavourable induction features (Bishop score of 4 or less), an initial dose of 2 mg should be administered vaginally. In other patients an initial dose of 1 mg should be administered vaginally.
In both groups of patients, a second dose of 1 mg or 2 mg may be administered after 6 hours as follows:
1 mg should be used where uterine activity is insufficient for satisfactory progress of labour.
2 mg may be used where response to the initial dose has been minimal.
Maximum dose 4 mg in unfavourable primigravida patients or 3 mg in other patients (see section 4.4).
Method of administration
Vaginally. The gel should be inserted high into the posterior fornix avoiding administration into the cervical canal. The patient should be instructed to remain recumbent for at least 30 minutes.
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Prostin E2 Vaginal Gel should not be used where the patient is sensitive to prostaglandins or other constituents of the gel.
Prostin E2 Vaginal Gel is not recommended in the following circumstances:
• For patients in whom oxytocic drugs are generally contra-indicated or where prolonged contractions of the uterus are considered inappropriate such as:
- Cases with a history of Caesarean section or major uterine surgery.
- Cases where there is cephalopelvic disproportion.
- Cases in which foetal malpresentation is present.
- Cases where there is clinical suspicion or definite evidence of pre-existing foetal distress.
- Cases in which there is a history of difficult labour and/or traumatic delivery.
- Grand multiparae with over five previous term pregnancies.
• Patients with ruptured membranes.
• In patients with a past history of, or existing, pelvic inflammatory disease, unless adequate prior treatment has been instituted.
• In patients where there is clinical suspicion or definite evidence of placenta praevia or unexplained vaginal bleeding during this pregnancy.
• Patients with active cardiac, pulmonary, renal or hepatic disease.
This product is only available to hospitals and clinics with specialised obstetric units and should only be used where 24-hour resident medical cover is provided.
Use the total contents of the syringe for one patient only. Discard after use. Use caution in handling the product to prevent contact with skin. Wash hands thoroughly with soap and water after administration.
Prostin E2 Vaginal Gel and Prostin E2 Vaginal Tablets are not bioequivalent.
Caution should be exercised in the administration of Prostin E2 Vaginal Gel for the induction of labour in patients with:
• asthma or a history of asthma
• epilepsy or a history of epilepsy
• glaucoma or raised intra-ocular pressure
• compromised cardiovascular, hepatic, or renal function
As with any oxytocic agent, Prostin E2 Vaginal Gel should be used with caution in patients with compromised (scarred) uteri.
In labour induction, cephalopelvic relationships should be carefully evaluated before use of Prostin E2 Vaginal Gel. During use, uterine activity, foetal status and the progression of cervical dilation should be carefully monitored to detect possible evidence of undesired responses, e.g. hypertonus, sustained uterine contractions, or foetal distress.
In cases where there is a known history of hypertonic uterine contractility or tetanic uterine contractions, it is recommended that uterine activity and the state of the foetus (where applicable) should be continuously monitored throughout labour. The possibility of uterine rupture should be borne in mind where high-tone uterine contractions are sustained.
Animal studies lasting several weeks at high doses have shown that prostaglandins of the E and F series can induce proliferation of bone. Such effects have also been noted in newborn infants who received prostaglandin E1 during prolonged treatment. There is no evidence that short-term administration of prostaglandin E2 can cause similar bone effects.
Women aged 35 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks have been shown to have an increased risk of post-partum disseminated intravascular coagulation. In addition, these factors may further increase the risk associated with labour induction (see section 4.8). Therefore, in these women, use of dinoprostone should be undertaken with caution. Measures should be applied to detect as soon as possible an evolving fibrinolysis in the immediate post-partum phase.
Since it has been found that prostaglandins potentiate the effect of oxytocin, it is not recommended that these drugs are used together. If used in sequence, the patient's uterine activity should be carefully monitored.
Prostin E2 Vaginal Gel is only used during pregnancy, to induce labour.
Prostaglandins are excreted in breast milk. This is not expected to be a hazard given the circumstances in which the product is used.
Cardiac disorders: Cardiac arrest
Vascular disorders: Hypertension
Gastrointestinal disorders: Diarrhoea, nausea, vomiting
General disorders and administration site conditions: Fever
Immune system disorders: Hypersensitivity reactions such as anaphylactoid reactions and anaphylactic reactions including anaphylactic shock
Musculoskeletal and connective tissue disorders: Back pain
Pregnancy, puerperium and perinatal conditions:
Maternal-related conditions: Uterine hypertonus, uterine rupture, abruptio placenta, pulmonary amniotic fluid embolism, rapid cervical dilatation
Fetes-related conditions: Uterine hypercontractility with/without foetal bradycardia foetal distress/altered foetal heart rate (FHR)
Neonatal conditions: Neonatal distress, neonatal death, stillbirths, low Apgar score
Reproductive system and breast disorders: Warm feeling in vagina, irritation, pain
Respiratory, thoracic and mediastinal disorders: Asthma, bronchospasm
Skin and subcutaneous tissue disorders: Rash
Blood and lymphatic system disorders: An increased risk of post-partum disseminated intravascular coagulation has been described in patients whose labour was induced by pharmacological means, either with dinoprostone or oxytocin (see section 4.4). The frequency of this adverse event, however, appears to be rare (<1 per 1,000 labours).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Overdosage may be expressed by uterine hypercontractility and uterine hypertonus. During use, uterine activity, fetal status and the progression of cervical dilation should be carefully monitored to detect possible evidence of undesired responses, e.g. hypertonus, sustained uterine contractions, or fetal distress. Because of the transient nature of prostaglandin E2 (PGE2)-induced myometrial hyperstimulation, non-specific, conservative management was found to be effective in the vast majority of cases: i.e. maternal position change and administration of oxygen to the mother. If conservative management is not effective, ß-adrenergic drugs may be used as a treatment of hyperstimulation following administration of PGE2 for cervical ripening, in appropriate patients.
Pharmacotherapeutic group: Prostaglandins, ATC-code: G02AD02
Dinoprostone is a prostaglandin of the E series which induces myometrial contractions and promotes cervical ripening.
When given vaginally, PGE2 is rapidly absorbed. Plasma levels of 15-keto PGE2 equivalents peak at 1.5 hours after administration of a 5 mg dose. In vitro work indicates that PGE2 is 73% bound to human plasma albumin. It is rapidly metabolised in the lungs, kidneys, spleen and liver, with a single pass of the circulatory system converting 90% of an injected PGE2 dose to metabolites.
There are no preclinical data of relevance which are additional to those already included in other sections of the Summary of Product Characteristics.
Colloidal silicon dioxide.
Store in a refrigerator at 2-8°C.
Carton containing one polyethylene syringe containing 3 g (or 2.5 ml) of clear, viscous gel.
Use the total contents of the syringe for one patient only. Discard after use. Use caution in handling this product to prevent contact with skin. Wash hands thoroughly with soap and water after administration.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Date of first authorisation: 30 April 1986
Date of latest renewal: 28 October 2004
Ref: PR 5_2
Ramsgate Road, Sandwich, Kent, CT13 9NJ
+44 (0)1304 616161
+44 (0)1304 616 161